Oragenics, Inc.
12085 Research Drive
Alachua
Florida
32615
United States
219 articles about Oragenics, Inc.
-
Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
9/15/2021
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced the initiation of a study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study.
-
Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants
8/30/2021
Oragenics, Inc. announces that the stabilized pre-fusion spike protein trimer produced by its Canadian collaborator and licensed by the Company from the National Institutes of Health (NIH) generates neutralizing antibodies in mice after immunization against SARS-CoV-2, when administered with several novel intramuscular and intranasal adjuvants.
-
Oragenics Announces Postponement of Annual Meeting of Shareholders
8/24/2021
Oragenics, Inc. today announced the Company’s reconvened annual meeting of shareholders, on August 23, 2021 at 4:00 p.m. was adjourned due to a lack of quorum.
-
Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines
7/27/2021
Oragenics, Inc. announced it has entered into a licensing agreement with the National Research Council of Canada that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.
-
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
7/1/2021
Oragenics, Inc. announced that the Company’s annual meeting of shareholders, on June 30, 2021, at 9:00 a.m. was convened and adjourned, without any business being conducted, due to lack of the required quorum.
-
Oragenics Issues Letter to Shareholders
5/18/2021
Executive Chairman Affirms Company Direction with Commitment to Speedy Execution of Business Strategy Highlights Deep Bench Strength Among Management, Board and Advisors in Vaccine Development and in Life Sciences
-
Oragenics Announce Changes in Management and Board of Directors
5/3/2021
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced that on May 2, 2021, Dr. Alan Joslyn resigned as Chief Executive Officer, President and director of Oragenics, Inc. to pursue other opportunities.
-
Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine
3/9/2021
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has entered into a material transfer agreement with Biodextris Inc. for the use of three intranasal mucosal adjuvants in the Company’s Terra CoV-2 vaccine against COVID-19. Adjuvants are added to vaccines to enhance their immunogenicity. BDX100, BDX300 and BDX301 are proteosome-based adjuvants comprised of proteins and lipopolysaccharides
-
Oragenics to Participate in Two Investment Conferences During March
3/8/2021
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), today announced that Alan Joslyn, Ph.D., President and Chief Executive Officer of Oragenics, will participate in two virtual investment conferences during the month of March, as follows: The H.C. Wainwright Global Life Sciences Virtual Conference with one-on-one meetings being held March 9-10, 2021
-
Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock
2/12/2021
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants.
-
SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice
2/2/2021
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announces that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National Institutes of Health (“NIH”) and licensed by the Company demonstrates protective immunity in immunized mice challenged with mouse-adapted SARS-CoV-2 virus.
-
Oragenics Issues Letter to Stockholders
1/14/2021
Oragenics, Inc. (NYSE American: OGEN) today issued the following letter to stockholders from its President and Chief Executive Officer, Alan Joslyn, Ph.D.: To My Fellow Stockholders, With so much encouraging news recently around COVID-19 vaccine development, this is an excellent time to update
-
Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies for COVID-19 Vaccine Adjuvant
1/7/2021
Oragenics, Inc. announced entering into a material transfer agreement with Adjuvance Technologies Inc. for use of the adjuvant TQL1055 in the Company’s Terra CoV-2 vaccine against COVID-19.
-
Oragenics, Inc. Announces $6.5 Million Registered Direct Offering
12/24/2020
Oragenics, Inc., a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, announced it has entered into definitive agreements with investors for the purchase and sale of 14,444,444 shares of its common stock at a purchase price of $0.45 per share in a registered direct offering.
-
Oragenics Announces Closing of $6.0 Million Underwritten Public Offering
11/24/2020
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, today announced, the closing of its previously announced underwritten public offering of 14,189,189 shares of common stock at a price to the public of $0.37 per share. Oragenics expects to receive gross proceeds of approximately $6.0 milli
-
Oragenics Prices $5.25 Million Common Stock Offering - Nov 20, 2020
11/20/2020
Oragenics, Inc., a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, announced the pricing of an underwritten public offering of 14,189,189 shares of its common stock at a price to the public of $0.37 per share.
-
Organics Announces Proposed Underwritten Public Offering - Nov 19, 2020
11/19/2020
Oragenics, Inc. a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, announced that it has commenced a proposed underwritten public offering of common stock of the Company.
-
FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccine
10/6/2020
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced receipt of feedback to its Type B Pre-IND Meeting Request from the U.S. Food and Drug Administration (“FDA”) that it is in broad agreement with the Company’s planned approach to clinical development of its SARS-CoV-2 vaccine, Terra CoV-2. As a r
-
Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine
9/28/2020
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) provides an update on U.S. federal government and other funding options the Company is pursuing in order to advance its SARS-CoV-2 vaccine, Terra CoV-2. Oragenics has been informed by the Biomedical Advanced Research and Development Authority (“BARDA”) of BARDA’s determination not to enter into negotiation with the Company. While BARDA noted the Com
-
Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference
9/11/2020
Oragenics, Inc. (NYSE American: OGEN) , a biopharmaceutical company dedicated to the development and commercialization of a vaccine candidate to combat the novel coronavirus pandemic (commonly referred to as COVID-19) today announces that Alan Joslyn, Ph.D., President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference (the “Conference”). The Conference is to